ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Rating of "Buy" by Analysts

Key Points

• ANI Pharmaceuticals has received an average rating of "Buy" from analysts, with the average 12-month target price set at $84.75.
• Recently, CFO Stephen P. Carey sold 50,000 shares for approximately $4.3 million, while analysts expect ANI Pharmaceuticals to report an earnings per share of 3.86 for the current year.
• The company's shares opened at $94.10, reflecting a 12-month high of $95.60 and a low of $52.50.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have received an average recommendation of "Buy" from the ten analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $84.75.

Several brokerages have commented on ANIP. Piper Sandler reissued an "overweight" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. HC Wainwright reissued a "buy" rating and set a $93.00 price target (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Zacks Research raised shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 21st. Guggenheim restated a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Finally, Truist Financial raised their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research note on Monday, August 11th.

Insider Transactions at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 50,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $86.07, for a total value of $4,303,500.00. Following the transaction, the chief financial officer owned 180,863 shares in the company, valued at $15,566,878.41. The trade was a 21.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Chad Gassert sold 20,000 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $86.97, for a total transaction of $1,739,400.00. Following the sale, the senior vice president owned 173,226 shares in the company, valued at approximately $15,065,465.22. The trade was a 10.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 405,538 shares of company stock worth $35,690,131 over the last quarter. Corporate insiders own 12.70% of the company's stock.

Institutional Trading of ANI Pharmaceuticals

Several large investors have recently modified their holdings of ANIP. Millennium Management LLC increased its holdings in ANI Pharmaceuticals by 89.3% during the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock valued at $55,437,000 after buying an additional 473,097 shares during the last quarter. Rubric Capital Management LP raised its holdings in ANI Pharmaceuticals by 354.7% in the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company's stock worth $16,813,000 after purchasing an additional 200,998 shares during the period. Aberdeen Group plc raised its holdings in ANI Pharmaceuticals by 76.1% in the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company's stock worth $28,059,000 after purchasing an additional 181,134 shares during the period. Woodline Partners LP purchased a new position in ANI Pharmaceuticals during the first quarter valued at $11,144,000. Finally, Deep Track Capital LP grew its holdings in ANI Pharmaceuticals by 28.6% during the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after purchasing an additional 144,214 shares during the period. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ ANIP opened at $94.10 on Wednesday. The firm has a fifty day simple moving average of $74.48 and a two-hundred day simple moving average of $67.55. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $95.60. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The firm has a market capitalization of $2.04 billion, a PE ratio of -122.21 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The business had revenue of $211.37 million during the quarter, compared to analyst estimates of $187.18 million. During the same period last year, the business posted $1.02 earnings per share. ANI Pharmaceuticals's quarterly revenue was up 53.2% compared to the same quarter last year. Equities analysts expect that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.